Major ReviewCurrent Concepts in the Etiology and Treatment of Behçet Disease
Section snippets
Definitions
Behçet disease (BD) was first described in 1937 by a Turkish dermatologist Dr. Hulusi Behçet from Istanbul as a triad of symptoms consisting of oral aphthae, genital ulcers, and hypopyon uveitis.50, 467 The disease is defined as a chronic, relapsing, multisystemic idiopathic inflammatory problem characterized by an episodic occlusive retinal vasculitis with no specific treatment,153 although there are some recent improvements regarding the management, especially of ocular BD, by new biological
Epidemiology
This ubiquitous disorder exhibits a distinct geographic variation and is endemically higher particularly in Turkey, Iraq, Iran, Korea and Japan, the population derived historically from the ancient Silk Road that was used for centuries as a trade-making passage from the East to the West.352 Behçet disease accounts for up to 20% of cases of endogenous uveitis in some of these countries, particularly in Japan and Turkey (when compared with only 0.2% in the USA), and the highest prevalence is
Frequency and Prevalence
The estimated prevalence of BD is between 1/10,000 and 1/1,000 in the Mediterranean countries, the Middle East, and the Far East. In Japan, the prevalence rate is about 1/10,000 and the disease occurs more frequently in the temperate northern than in subtropical southern parts of Japan, again suggesting environmental factors influencing the prevalence of the disease. In Turkey, the prevalence is 2–42 cases per 10,000, depending on the geographical differences.40, 71, 211 In Asia, it is
Age, Sex, and Severity
Although BD affects primarily young adults more frequently between the second and fourth decade of life and is rarely seen in children, the onset can occur at any age from infants to the elderly.58, 155, 254, 352, 458, 465 In general, the mean age of onset is the third decade of life.
Behçet disease is more common in men than in women with a 2–10:1 male:female ratio in the ancient Silk Road countries, whereas the trend is reversed in Western Europe and the USA.155, 352, 458 Indeed, male
Morbidity and Mortality
In general, the “disease burden” of BD is usually confined to the early years of its course that “burns out” during the following years. Although severe orogenital ulcerations can be debilitating for BD patients with a lower oral intake, the effects of the disease may be cumulative for CNS and vascular diseases, and the leading cause of chronic morbidity is high especially with ophthalmic inflammation. Indeed, overall survival analysis suggests that the risk of visual loss increases
Etiopathogenesis and Effector Mechanisms
The intermittent nature of the disease and the lack of consistent response to therapy make the underlying etiology difficult to define. However, it is probably mediated by a combination of genetics,116, 384 infectious agents,98, 352 immune dysregulation and inflammatory mediators,155, 200, 360 heat shock proteins (HSPs),439 oxidative stress,83, 463 lipid peroxidation (LPO),477 and environmental factors. Raised levels of circulating immune complexes, complements and acute phase proteins,
Immunohistopathology
Immunohistopathologic studies of specimens taken from active inflammatory sites of BD patients support the findings of those found in the peripheral blood and indicate immune-complex mediated disease. Necrotizing, neutrophilic (leukocytoclastic) obliterative perivasculitis (phlebitis) and venous thrombosis with lymphocytic and monocytic cellular infiltration of the veins, capillaries and the arteries of all sizes, with or without fibrin deposition in the vessel wall, is the hallmark of BD.153
Clinical Features
Ophthalmologists are concerned with the ocular inflammation and, in particular, retinal vasculitis during the course of BD. However, BD may produce distressing symptoms with the combinations of variable systemic involvements. It presents by exacerbations and remissions with varying healing time among patients. Although the severity of disease generally diminishes with time and stabilizes at any moment, it may become chronic in a given organ system.98, 155, 197, 364 Therefore, ophthalmologists
Treatment
Treatment of BD is symptomatic and empirical. The main objectives of a physician are the following: 1) to control and treat symptoms associated with mucocutaneous lesions; 2) to relieve the pain, discomfort, and functional disability; 3) to suppress and control active inflammation; 4) to reduce the frequency and severity of recurrences; and 5) to prevent end-organ damage.157
On the other hand, the ultimate goals of the ophthalmologist in treating this potentially blinding ocular disease for
Conclusion and Future Directions
We currently know considerably much more about BD as compared with two to three decades ago, and we can do more regarding the early diagnosis, follow-up, and treatment of the disease. Although a number of novel treatment opportunities have recently been introduced, no safe and conclusive treatment exists yet. Therefore, the outcome is still not satisfactory and clinical dilemmas continue to challenge, especially in sight-threatening panuveitis that is refractory to traditional therapy. Indeed,
Method of Literature Search
This article was prepared by using the database of National Library of Medicine by using the search words Behçet's disease or Behçet's syndrome from 1994 up to February 2005, our own published papers, and manual searches based upon articles cited in the texts of other articles. Many of the relevant full articles were obtained by personal communication with relevant authors, or downloaded, where available. Articles were included if they emanated from peer-reviewed journals. Clinical studies were
References (515)
- et al.
Behçet's disease with pulmonary involvement, superior vena cava syndrome, chyloptysis and chylous ascites
Respir Med
(1996) - et al.
Behçet's disease and hearing loss
Auris Nasus Larynx
(2004) - et al.
Renal Behçet's disease: a cumulative analysis
Semin Arthritis Rheum
(2002) - et al.
Neuro-Behçet's disease in Iraq: a study of 40 patients
J Neurol Sci
(1999) - et al.
Cerebral vein thrombosis in Behçet's disease
Pediatr Neurol
(2001) - et al.
Epidemiological features and visual prognosis of Behçet's disease
Jpn J Ophthalmol
(1999) - et al.
Elevated FVIII and FIX level in a Behçet's disease patient with intracardiac thrombosis and pulmonary arterial aneurysms
Thromb Res
(2005) - et al.
Blood serum interleukin-1 receptor antagonist in pars planitis and ocular Behçet disease
Am J Ophthalmol
(1997) - et al.
Immunopathology of the noninfectious posterior and intermediate uveitides
Surv Ophthalmol
(2001) - et al.
Thalidomide: current and potential clinical applications
Am J Med
(2000)
Bladder involvement in Behçet's syndrome
J Urol
Vascular endothelial function and oxidative stress mechanisms in patients with Behçet's syndrome
J Am Coll Cardiol
Clinical features of patients with Behçet's disease and epididymitis
J Urol
Homocysteine and thrombotic disease
Blood
Treatment of recurrent ulceration with low doses of thalidomide: pilot study in 17 patients
Rev Med Interne
Thalidomide inhibits tumor necrosis factor-α production and antigen presentation by Langerhans cells
J Invest Dermatol
Polymorphonuclear leukocyte myeloperoxidase levels in patients with Behçet's disease
Clin Exp Rheumatol
Azathiopine-steroid combination therapy for pulmonary arterial aneurysms in Behçet's disease
Rheumatol Int
Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behçet's disease
J Eur Acad Dermatol Venereol
Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC
Hum Mol Genet
Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polymorphisms?
Arthritis Rheum
Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behçet's disease
Ann Acad Med Singapore
Cranial MRI in Behçet's disease: 134 examinations of 98 patients
Neuroradiology
Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group
Brain
Behçet's disease and renal failure
Nephrol Dial Transplant
Prevalences of hepatitis A, B, C and E viruses in Behçet's disease
Rheumatology (Oxford)
Hyperhomocysteinaemia in Behçet's disease
Rheumatology (Oxford)
Prevalence and patterns of neurological involvement in Behçet's disease: a prospective study from Iraq
J Neurol Neurosurg Psychiatry
Resistant bipolar disorder precipitated by Behçet's syndrome
Bipolar Disord
Review of the chronology of clinical manifestations in 60 patients with Behçet's disease
Dermatology
Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study
Arch Dermatol
Androgen receptor levels of oral and genital ulcers and skin pathergy test in patients with Behçet's disease
Dermatology
The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study
Arch Dermatol
Histological and immunofluorescence findings of non-follicular papulopustular lesions in patients with Behçet's disease
J Eur Acad Dermatol Venereol
Glomerulonephritis in Behçet's disease: report of seven cases and review of the literature
Clin Rheumatol
Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behçet's disease
Arthritis Rheum
[Treatment of severe Behçet's disease with anti-TNF-α: infliximab. A case report]
Ann Med Interne (Paris)
Treatment of refractory vitritis in Behçet disease with infliximab
Arthritis Rheum
Serum Levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behçet's disease
J Dermatol
The effects of nitric oxide donors and inhibitors on neutrophil functions in Behçet's disease
Clin Exp Rheumatol
Serum homocysteine level is higher in Behcet's disease with vascular involvement
Rheumatol Int
The efficacy of cyclosporin A in the treatment of Behçet's disease
Ophthalmic Surg
Retinal and disc neovascularization in Behçet's disease and efficacy of laser photocoagulation
Graefes Arch Clin Exp Ophthalmol
Fluorescein and indocyanine green angiography findings in Behçet's disease
Br J Ophthalmol
Helicobacter pylori and Behçet's disease
Dermatology
Etanercept treatment in the endotoxin-induced uveitis of rats
Exp Eye Res
Serum beta 2-microglobulin reflects disease activity in Behçet's disease
Rheumatol Int
Epileptic seizures in Behçet disease
Epilepsia
Prevalence of Behçet's disease in Istanbul, Turkey
Int J Dermatol
Interferon alfa-2a in the treatment of Behçet's disease
Dermatology
Cited by (368)
The Role of Colchicine in Different Clinical Phenotypes of Behcet Disease
2023, Clinical TherapeuticsChoroidal vascularity index and submacular choroidal thickness in patients with Behçet disease assessed with enhanced-depth OCT
2023, Canadian Journal of OphthalmologyJAK-STAT signaling pathway in non-infectious uveitis
2022, Biochemical PharmacologyNeuro-Behcet's syndrome: Case report and literature review
2022, Radiology Case ReportsDiagnostic and therapeutic considerations in pediatric uveitis
2024, Spektrum der Augenheilkunde
The author reported no proprietary or commerical interest in any product mentioned or concept discussed in this article.